Why are biosimilars much more complex than generics?
Main Author: | Eduardo Pagani |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Israelita de Ensino e Pesquisa Albert Einstein
|
Series: | Einstein (São Paulo) |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082019000100100&lng=en&tlng=en |
Similar Items
ACPAs Are Much More Than Diagnostic Autoantibodies
by: Abdulla Watad, et al.
Published: (2016-10-01)
by: Abdulla Watad, et al.
Published: (2016-10-01)
Similar Items
-
Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
by: Ranjan Gupta
Published: (2020-01-01) -
From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01) -
Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
by: B Oza, et al.
Published: (2019-01-01) -
Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020-04-01) -
Why Is There So Much More Research on Vision Than on Any Other Sensory Modality?
by: Fabian Hutmacher
Published: (2019-10-01)